HCmed Innovations Co., Ltd. (TPE:6934)
Taiwan · Delayed Price · Currency is TWD 74.20
+1.10 (1.50%)
At close: Aug 25, 2026
HCmed Innovations Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 109.19 | 100.23 | 141.61 | 9.24 | 6.48 | 54.06 | |
Revenue Growth | -18.28% | -29.22% | 1433.43% | 42.56% | -88.02% | 67.23% |
Cost of Revenue | 97.57 | 75.31 | 41.96 | 35.38 | 37.25 | 19.41 |
Gross Profit | 11.62 | 24.92 | 99.65 | -26.15 | -30.77 | 34.65 |
Selling, General & Admin | 87.94 | 79.28 | 63.91 | 49.94 | 48.38 | 20.75 |
Research & Development | 54.39 | 65.29 | 73.34 | 67.67 | 66.85 | 43.31 |
Amortization of Goodwill & Intangibles | - | - | - | - | - | 11.45 |
Operating Expenses | 141.56 | 144.61 | 137.24 | 117.61 | 115.24 | 75.51 |
Operating Income | -129.94 | -119.69 | -37.59 | -143.76 | -146 | -40.87 |
Interest Expense | -2.22 | -1.53 | -0.24 | -0.29 | -0.06 | -0.05 |
Interest & Investment Income | 4.53 | 3.28 | 2.48 | 0.83 | 0.32 | 0.19 |
Earnings From Equity Investments | - | - | - | - | -0.19 | -1.57 |
Currency Exchange Gain (Loss) | 1.03 | 1.03 | 1.44 | 0.01 | 0.24 | -0.38 |
Other Non Operating Income (Expenses) | 13.84 | 0.01 | 0.05 | 0.15 | 0.04 | 0.06 |
EBT Excluding Unusual Items | -112.77 | -116.89 | -33.86 | -143.07 | -145.65 | -42.62 |
Impairment of Goodwill | - | - | -12.16 | -23.33 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | 1.63 | - |
Asset Writedown | -11.86 | -11.86 | -4.91 | - | - | - |
Other Unusual Items | 0.02 | 0.02 | - | - | - | 2.43 |
Pretax Income | -124.6 | -128.73 | -50.93 | -166.4 | -144.03 | -40.19 |
Income Tax Expense | 0.01 | -2.62 | 27.29 | -0.47 | -0.24 | - |
Net Income | -124.61 | -126.11 | -78.21 | -165.93 | -143.79 | -40.19 |
Net Income to Common | -124.61 | -126.11 | -78.21 | -165.93 | -143.79 | -40.19 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 34 | 32 | 30 | 27 | 22 | 18 |
Shares Outstanding (Diluted) | 34 | 32 | 30 | 27 | 22 | 18 |
Shares Change | 10.67% | 7.03% | 13.06% | 23.01% | 23.04% | 0.63% |
EPS (Basic) | -3.66 | -3.92 | -2.60 | -6.25 | -6.66 | -2.29 |
EPS (Diluted) | -3.66 | -3.92 | -2.60 | -6.25 | -6.66 | -2.29 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -159.22 | -124.2 | -43.38 | -127.74 | -87.95 | -19.82 |
Free Cash Flow Per Share | -4.67 | -3.86 | -1.44 | -4.81 | -4.07 | -1.13 |
Gross Margin | 10.64% | 24.86% | 70.37% | -283.14% | - | 64.10% |
Operating Margin | -119.00% | -119.41% | -26.55% | -1556.70% | -2253.83% | -75.60% |
Profit Margin | -114.12% | -125.82% | -55.23% | -1796.71% | -2219.67% | -74.34% |
Free Cash Flow Margin | -145.81% | -123.91% | -30.63% | -1383.17% | -1357.64% | -36.67% |
EBITDA | -114.45 | -109.17 | -27.11 | -132.84 | -138.36 | -37.17 |
EBITDA Margin | -104.82% | -108.92% | -19.15% | - | - | -68.76% |
D&A For EBITDA | 15.49 | 10.52 | 10.48 | 10.92 | 7.64 | 3.7 |
EBIT | -129.94 | -119.69 | -37.59 | -143.76 | -146 | -40.87 |
EBIT Margin | -119.00% | -119.41% | -26.55% | - | - | -75.60% |